tiprankstipranks
Clene Nosedives After Lead Candidate Fails ALS Trial
Market News

Clene Nosedives After Lead Candidate Fails ALS Trial

Shares of biotech company Clene (NASDAQ:CLNN) are tanking today after its lead product candidate CNM-Au8 failed to meet the primary endpoint in amyotrophic lateral sclerosis (ALS) trial.

ALS is a rare neurological condition.

Is CLNN Stock a Buy?

Despite the ~56.3% slide in CLNN price so far this year, the Street sees a massive 541.03% potential upside in the stock based on an average price target of $12.50.

Further, the stock has a Strong Buy consensus rating based on three unanimous Buys.

Read full Disclosure

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles